Outcome of a structured surveillance programme in women with a familial predisposition for breast cancer

European Journal of Cancer Prevention

Volumn 15, Issue 6, 2006, Pages 483-489

  Schmutzler, Rita K ^a,d   Rhiem, Kerstin ^a   Breuer, Petra ^a   Wardelmann, Eva ^a   Lehnert, Martin ^b   Coburger, Silke ^c   Wappenschmidt, Barbara ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c National Institute of Public Health   (Czech Republic)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Breast cancer 1 gene; Breast cancer 2 gene; Breast carcinoma; Hereditary cancer syndrome; Incidence; Surveillance

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CYTODIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER RISK; CANCER SIZE; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY DIAGNOSIS; ECHOMAMMOGRAPHY; FEMALE; GENE MUTATION; HEALTH PROGRAM; HEALTH SURVEY; HERITABILITY; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRECANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FALSE POSITIVE REACTIONS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; RISK;

EID: 33751062803     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cej.0000220624.70234.14     Document Type: Article

References (29)

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117-1130.
2. Armitage P, Colton Th (1998). Encyclopedia of biostatistics. Chichester, Sussex, UK: Wiley.
3. Boetes C (2002). The evaluation of women with familial risk of breast cancer. J Exp Clin Cancer Res 21:97-101.
4. Breast Cancer Information Core (BIC) database [Accessed 25 February 2005; http://www.nhgri.nih.gov/Intramural.research/Laboratorytransfer/Bic/index.html] .
5. Brekelmans CT, Seynaeve C, Bartels CC, Tilanus-Linthorst MM, Meijers-Heijboer EJ, Crepin CM, et al. (2001). Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19:924-930.
6. Brown J, Buckley D, Coulthard A, Dixon AK, Dixon JM, Easton DF, et al. (2000). Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Screening Study Advisory Group. Magn Reson Imaging 18:765-776.
7. Epidemiologic Cancer Registry Münster [Accessed 25 February 2005; at http://medweb.uni-muenster.de/institute/epikrebs].
8. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689.
9. German Consortium for Hereditary Breast and Ovarian Cancer (2002). Comprehensive analysis of 989 patients with breast and/or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the german population. Int J Cancer 97:472-480.
10. Gui GPH, Hogben RKF, Walsh G, A'Hern R, Eeles R (2001). The incidence of breast cancer from screening woman according to predicted family history risk: does annual clinical examination add to mammography? Eur J Cancer 37:1668-1673.
11. Hoogerbrugge N, Bult P, de Widt-Levert LM, Beex LV, Kiemeney LA, Ligtenberg MJ, et al. (2003). High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 21:41-45.
12. Kauff ND, Brogi E, Scheuer L, Pathak DR, Borgen PI, Hudis CA, et al. (2003). Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 97:1601-1608.
13. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. (2002). Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615.
14. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. (2001). National Breast and Bowel Project NSABP-P breast cancer prevention trial. JAMA 286:2251-2256.
15. Kollias J, Sibbering DM, Blamey RW, Holland PA, Obuszko Z, Wilson AR, et al. (1998). Screening women aged less than 50 years with a family history of breast cancer. Eur J Cancer 34:878-883.
16. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. (2004). Efficacy of MRI and mammography for breast-cacner screening in women with a familial or genetic predisposition. N Engl J Med 351:427-500.
17. Kuhl CK, Schmutzler RK, Leutner CC, Kempe A, Wardelmann E, Hocke A, et al. (2000). Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 215:267-279.
18. Kuhl CK, Schrading S., Leutner CC, Morakkabati N, Trog D, Schmutzler RK, Schild HH (2003). Surveillance of 'high risk' women with proven or suspected familial (hereditary) breast cancer: First mid-term results of a multi-modality clinical screening trial. Chicago: American Society of Clinical Oncology (ASCO) Annual Meeting. [Abstract].
19. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. (2001). Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164.
20. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al. (2004). Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328-2335.
21. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. (2002). Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622.
22. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, et al. (2003). A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8-R17.
23. Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, et al. (2002). Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260-1268.
24. Stoutjesdijk MJ, Boetes C, Jager GJ, Beex L, Bult P, Hendriks JH (2001). Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 93:1095-1102.
25. Tilanus-Linthorst M, Verhoog L, Obdeijn IM, Bartels K, Menke-Pluymers M, Eggermont A, et al. (2002). A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumour independently contribute to a frequent false-negative mammography. Int J Cancer 102:91-95.
26. Tilanus-Linthorst MM, Bartels CC, Obdeijn AI, Oudkerk M (2000). Earlier detection of breast cancer by surveillance of women at familial risk. Eur J Cancer 36:514-519.
27. Tilanus-Linthorst MMA, Kriege M, Boetes C, Hop WCJ, Obdeijn IM, Oosterwijk JC, et al. (2005). Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer 41:1610-1617.
28. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. (2004). Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317-1325.
29. Warner E, Plewes DB, Shumak RS, Catzavelos GC, Di Prospero LS, Yaffe MJ, et al. (2001). Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 19:3524-3531.